Table 3.
Univariate survival analysis.
| Variables | PFS (MST: days) | p value | OS (MST: days) | p value |
|---|---|---|---|---|
|
Age ≤ 69/> 69 years |
196/216 | 0.50 | NR/437 | 0.21 |
|
Gender Male/female |
240/203 | 0.46 | 637/490 | 0.38 |
|
Smoking Yes/no |
240/196 | 0.93 | 637/490 | 0.63 |
|
PS 0–1/2–3 |
324/168 | 0.18 | 568/324 | 0.54 |
|
Histology AC/non-AC |
388/167 | 0.06 | 637/317 | 0.05 |
|
Distant meta Yes/no |
203/361 | 0.75 | 437/568 | 0.51 |
|
ILD Yes/no |
388/196 | 0.39 | 490/568 | 0.87 |
|
Extracranial radiation Yes/no |
196/240 | 0.93 | 568/637 | 0.36 |
|
BMI High/low |
196/240 | 0.45 | 779/490 | 0.31 |
|
NLR High/low |
196/216 | 0.66 | NR/568 | 0.77 |
|
CRP ≤ 1.0/> 1.0 |
361/167 | 0.11 | 568/437 | 0.21 |
|
SUVmax High/low |
164/244 | 0.60 | 568/490 | 0.91 |
|
MTV High/low |
104/244 | 0.32 | 124/637 | 0.04 |
|
TLG High/low |
167/324 | 0.21 | 203/568 | 0.13 |
|
PD-L1 ≤ 75/> 75 (%) |
324/203 | 0.52 | 568/490 | 0.73 |
|
Brain metastases Yes/no |
456/196 | 0.07 | 637/437 | 0.64 |
|
Bone metastasis Yes/no |
203/296 | 0.86 | 437/568 | 0.87 |
|
Liver metastasis Yes/no |
65/240 | 0.58 | 114/568 | 0.10 |
PFS progression free survival, OS overall survival, MST median survival time, PS performance status, AC adenocarcinoma, ILD interstitial lung disease, BMI body mass index, NLR neutrophil to lymphocyte ratio, CRP C-reactive protein, TLG total lesion glycolysis, MTV metabolic tumor volume, SUVmax the maximum of standardized uptake value, PD-L1 programmed death ligand-1.
Bold means statistical significance.